With respect to initiation of ADT, the TROG 03.06 and VCOG PR 01-03: The Timing Of Androgen Deprivation
Therapy In Prostate Cancer Patients With A Rising PSA (TOAD) Collaborative Randomised Phase III Trial examined 293 patients with PSA relapse after definitive therapy to compare if immediate ADT versus delayed ADT affected OS.
During the in-between age of 75-79 years, half had radiation therapy, 24% expectant management, 20% primary androgen deprivation
therapy, and just 6% radical prostatectomy.
Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation
therapy: SWOG S1014.
Loss of libido, vasomotor flushing, fatigue, anemia, and increased risk of osteoporosis are among the adverse events associated with androgen deprivation
, said Dr.
therapy, which is commonly used to treat men with prostate cancer, causes weight gain, thus predisposing men to diabetes and the metabolic syndrome.
This NDA submission for apalutamide was based on the company's Phase 3 data from the pivotal ARN-509-003 (SPARTAN) clinical trial, which assessed the safety and efficacy of apalutamide versus placebo in men with non-metastatic CRPC who have a rapidly rising prostate specific antigen (PSA) despite receiving continuous androgen deprivation
Accurate assignment of biopsy Gleason sum is important, especially when a patient chooses radiotherapy instead of surgery, as the recommended duration of adjuvant androgen deprivation
is different for a patient considered high-risk (Gleason [greater than or equal to]8) compared to a patient considered intermediate-risk (Gleason [less than or equal to]7).[sup.10] The purpose of this study was to review a cohort of men who had discordant prostate biopsy sums and were treated with radical prostatectomy.
Washington, Apr 27 (ANI): Prostate cancer patients who undergo therapy to increase testosterone levels are more likely to suffer from bone- and heart-related problems, says a new study.he research team, led by Lockwood Taylor, MPH, of the University of Texas Health Science Centre, revealed that androgen deprivation
therapy (ADT) used to increase testosterone levels can cause a variety of side effects including skeletal and cardiovascular complications, sexual dysfunction, periodontal disease, and mood disorders.
A total of 43 patients had definitive treatment with surgery, radiation, or androgen deprivation
after at least 6 months of active surveillance.
ORLANDO -- Toremifene citrate, a selective estrogen receptor modulator, increased bone mineral density and improved lipid levels in men receiving androgen deprivation
therapy for advanced prostate cancer, investigators reported at a symposium on prostate cancer sponsored by the American Society of Clinical Oncology,
Thanks to the approval, abiraterone acetate plus prednisone/prednisolone is now indicated for the treatment of newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation
Although the use of androgen deprivation
has been with us for over 60 years, we continue to learn more and more about the androgen axis, how best to suppress it, and how to maximize the metabolic challenges that it poses for our patients.
Men who received androgen deprivation
therapy to treat their prostate cancer were also found to have an increased risk of bone disorders.
They found that for the 8-year period studied, 42% of localized prostate cancer patients aged 65 and older underwent radiation therapy, 21% had a radical 17% had primary androgen deprivation
therapy, and 20% had expectant management.